Report Description Table of Contents Gastrointestinal Devices Market: Screening, Therapeutic Endoscopy and Digital Imaging Expand Procedure-Based Demand The Global Gastrointestinal (GI) Devices Market was valued at USD 16.46 billion in 2025 and is projected to reach USD 25.08 billion by 2032, growing at a CAGR of 6.2% during 2026–2032, according to Strategic Market Research. Recent FDA approvals in gastrointestinal (GI) devices have focused on AI-based diagnostics, neuromodulation therapies, and improved testing tools that enhance accuracy and patient outcomes. The Rectal Expulsion Device provides a simple, non-invasive method to assess constipation and pelvic floor dysfunction, especially useful in primary care. NaviCam ProScan is an AI-enabled capsule endoscopy system designed to detect small bowel bleeding and mucosal lesions with higher precision. Magentiq-Colo is real-time AI software that improves polyp detection during colonoscopy. In therapeutics, IB-Stim is a neurostimulation device used to manage functional abdominal pain in adults and children, highlighting growing adoption of neuromodulation in GI care. Pipeline innovations are also advancing GI diagnostics and intervention, including the WATS3D system (Breakthrough Device designation), a digital pathology tool for earlier esophageal cancer detection. Endoscopy is further evolving through robotic systems, single-use disposable scopes that reduce infection risk, and motorized platforms that improve navigation and procedural precision. Gastrointestinal (GI) devices are used to diagnose, monitor, and treat the digestive tract and include endoscopes, procedure accessories, enteral feeding tubes, and bariatric or motility devices such as gastric balloons and capsules. Diagnostic endoscopes include gastroscopes (upper GI tract), colonoscopes (colon and rectum), duodenoscopes (bile and pancreatic duct access for ERCP), enteroscopes (small intestine), and capsule endoscopes (ingestible cameras for small bowel imaging). Therapeutic accessories include biopsy forceps for tissue sampling, snares for polyp removal, hemostasis clips for bleeding control, balloon dilators for strictures, and retrieval baskets or nets for removing stones or foreign bodies. Enteral support devices include NG, PEG, and jejunostomy feeding tubes, while bariatric devices include gastric balloons and lap bands, and stents are used to keep blocked ducts or bowel segments open. Procedure volume remains one of the strongest indicators of demand. The United States recorded 23.52 million GI endoscopic procedures in 2022, including 15.47 million colonoscopies and 7.25 million upper endoscopies. The same analysis recorded 276,868 upper EUS procedures and 185,763 ERCP procedures. Gastrointestinal Devices Market Segmentation, Revenue Estimation and Forecast Using the USD 16.46 billion 2025 market value and USD 25.08 billion 2032 forecast as the control totals, segment revenue estimates show endoscopic devices, colorectal cancer applications, hospitals and endoscopy technology holding the largest positions in their respective categories. By Product Type Endoscopic Devices account for an estimated 40.0% share in 2025, representing USD 6.58 billion, and are projected to reach approximately USD 10.28 billion by 2032 at a CAGR of 6.6%. Their leading position reflects high colonoscopy and upper-endoscopy volumes, along with continued investment in improved imaging and treatment systems. Laparoscopic Devices represent approximately 23.0% or USD 3.79 billion in 2025 and are projected to reach USD 5.52 billion by 2032, growing at a CAGR of 5.5%. Demand remains steady as hospitals increasingly use minimally invasive procedures to shorten recovery times and reduce hospital stays. Gastrointestinal Stents account for approximately USD 1.65 billion in 2025 and are projected to reach USD 2.51 billion by 2032 at a CAGR of 6.2%. Growth is linked to their expanding use in managing blockages caused by gastrointestinal cancers and other digestive conditions. Biopsy Devices represent approximately USD 1.32 billion in 2025 and are expected to reach USD 2.01 billion by 2032 at a CAGR of 6.2%. The segment benefits from rising cancer screening and the need for tissue samples to confirm gastrointestinal diseases. Hemostasis Devices are estimated at USD 1.15 billion in 2025 and could reach USD 1.88 billion by 2032, registering a comparatively strong CAGR of 7.3%. Growth reflects the increasing use of endoscopic procedures to control gastrointestinal bleeding without major surgery. Enteral Feeding Devices account for approximately USD 1.15 billion in 2025 and are forecast to reach USD 1.63 billion by 2032 at a CAGR of 5.1%. Demand comes from patients who cannot consume sufficient nutrition normally, particularly those receiving long-term hospital, cancer or elderly care. Other GI devices represent approximately USD 0.82 billion in 2025 and are projected to reach USD 1.25 billion by 2032 at a CAGR of 6.2%. This category includes supporting products used across diagnostic, surgical and patient-care procedures, with demand rising alongside overall gastrointestinal treatment volumes. By Disease Type Colorectal Cancer represents the largest disease-related segment at approximately 26.0% or USD 4.28 billion in 2025. The segment is projected to reach USD 6.77 billion by 2032 at a CAGR of 6.8%, reflecting the large number of screening colonoscopies, biopsies, polyp-removal procedures and follow-up examinations. GERD accounts for USD 3.79 billion in 2025 and is projected to reach USD 5.52 billion by 2032 at a CAGR of 5.5%. Its sizable share is linked to the high number of patients requiring diagnosis, symptom monitoring and treatment when medication does not provide adequate relief. Inflammatory Bowel Disease (IBD) represents USD 2.63 billion in 2025 and is forecast to reach USD 4.14 billion by 2032 at a CAGR of 6.7%. Because Crohn’s disease and ulcerative colitis require ongoing assessment, many patients undergo repeated examinations throughout their treatment. Gastrointestinal Bleeding accounts for approximately USD 2.30 billion in 2025 and is projected to reach USD 3.64 billion by 2032 at a CAGR of 6.8%. Demand is increasing as hospitals use endoscopic devices to identify bleeding sites and provide treatment during the same procedure. Peptic Ulcers represent approximately USD 1.48 billion in 2025 and are expected to reach USD 2.01 billion by 2032 at a CAGR of 4.5%. Growth remains moderate because many cases are managed with medication, although diagnostic and emergency procedures remain necessary for severe or complicated ulcers. Other gastrointestinal diseases collectively account for approximately USD 1.98 billion in 2025 and are forecast to reach USD 3.00 billion by 2032 at a CAGR of approximately 6.1%. The segment covers several digestive conditions that require diagnosis, monitoring, feeding assistance or surgical care, creating broad demand across the device market. By End User Hospitals lead with approximately 52.0% of the market, or USD 8.56 billion in 2025, and are projected to reach USD 12.29 billion by 2032 at a CAGR of 5.3%. Hospitals retain the largest share because complex procedures for GI bleeding, cancer and bile duct disorders remain concentrated in facilities with specialist teams and advanced equipment. Ambulatory Surgical Centers (ASCs) represent approximately USD 4.12 billion in 2025 and are projected to reach USD 7.02 billion by 2032, registering a strong CAGR of 7.9%. The segment is growing as suitable endoscopic and minimally invasive procedures move to lower-cost outpatient settings that allow patients to return home sooner. Specialty Clinics account for approximately USD 2.30 billion in 2025 and are forecast to reach USD 3.64 billion by 2032 at a CAGR of 6.7%. Their growth reflects increasing demand for focused digestive care, routine endoscopy and follow-up services outside large hospitals. Diagnostic Centers represent approximately USD 1.48 billion in 2025 and are projected to reach USD 2.13 billion by 2032 at a CAGR of 5.3%. These centers benefit from expanding screening programs and rising referrals for early detection of colorectal cancer and other gastrointestinal conditions. By Technology Endoscopy dominates the technology segment with approximately 54.0% share or USD 8.89 billion in 2025. It is projected to reach USD 13.29 billion by 2032 at a CAGR of 5.9%, reflecting its wide use in colorectal screening, upper-GI diagnosis, bleeding control, biopsy and treatment procedures. Laparoscopy accounts for approximately USD 3.95 billion in 2025 and is projected to reach USD 5.52 billion by 2032 at a CAGR of 4.9%. Demand remains stable because the approach is widely used for gastrointestinal operations that require smaller incisions and shorter recovery periods. Robotics-Assisted Surgery represents a smaller USD 0.99 billion market in 2025 but is projected to reach approximately USD 2.01 billion by 2032, making it the fastest-growing technology segment at approximately 10.6% CAGR. Expansion is linked to rising hospital investment in robotic systems for complex gastrointestinal procedures that require greater surgical control. Capsule Endoscopy is estimated at USD 1.15 billion in 2025 and is projected to reach USD 1.76 billion by 2032 at a CAGR of 6.3%. Its use is increasing because it offers a less invasive way to examine areas of the small intestine that may be difficult to assess through conventional endoscopy. AI-Based Imaging accounts for approximately USD 1.48 billion in 2025 and is forecast to reach USD 2.50 billion by 2032 at a CAGR of 7.8%. Growth reflects the increasing use of image-assistance tools that help clinicians identify polyps and other abnormalities during gastrointestinal examinations. Colorectal Screening Sustains High-Volume Device Demand Colonoscopy represents the largest directly measured GI endoscopy category in the United States. Colorectal screening therefore provides one of the most repeatable sources of demand for gastrointestinal devices. NCI SEER projects approximately 158,850 new colorectal cancer cases and 55,230 deaths in the United States in 2026. Colonoscopy contributes to prevention, diagnosis and surveillance because precancerous polyps can be identified and removed during the procedure. The U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75 years. European screening policy also supports organized colorectal cancer screening and follow-up colonoscopy. IBD creates another surveillance population. The CDC estimates approximately 2.4 million to 3.1 million Americans have IBD, while global GBD data indicate approximately 3.83 million prevalent cases. Repeated colonoscopy for disease assessment and cancer surveillance creates recurring utilization of imaging, biopsy and therapeutic products. Therapeutic Endoscopy Expands Revenue per Procedure Gastrointestinal bleeding illustrates the expansion of endoscopy from diagnosis into treatment. NIDDK reports more than 1.5 million U.S. healthcare visits and approximately 500,000 hospital stays annually involving GI bleeding. Acute cases can require endoscopic evaluation followed by clipping or other hemostatic intervention, creating direct demand for disposable therapeutic products. Biliary disease adds another device-intensive procedure pathway. Nearly 25 million people in the United States have gallstones, with close to one million diagnoses annually. Patients with bile-duct stones, strictures or obstruction can require ERCP, extraction devices, guidewires, balloons or stents. The United States recorded 185,763 ERCP procedures in 2022. Although this volume is much smaller than colonoscopy, the number of specialized devices used during each intervention makes ERCP commercially significant. Endoscopic ultrasound is expanding in pancreatic and biliary care. Olympus and Canon launched the Aplio i800 EUS system in the United States in May 2026, while PENTAX Medical renewed its EUS collaboration with Fujifilm during 2026. Infection Control Changes Endoscopy Product Development Infection-control requirements are influencing gastrointestinal endoscope design, especially in duodenoscopy. The FDA has documented contamination concerns associated with reusable duodenoscopes and encouraged transition toward designs that simplify reprocessing or use disposable components. This has opened additional space for removable components and single-use scopes without eliminating reusable systems. High-volume hospitals continue to use reusable platforms because the same equipment supports many procedures, while disposable models gain relevance where contamination risk and reprocessing requirements carry greater weight. Ambu has built its GI portfolio around single-use gastroscopes and duodenoscopes, while established reusable-platform companies continue redesigning systems around infection prevention and easier reprocessing. AI-Based Imaging Moves Into Commercial Endoscopy Platforms Artificial intelligence has become a growing competitive layer within gastrointestinal imaging. Medtronic received CE Mark in February 2026 for its next-generation GI Genius module and ColonPRO software, extending its AI-assisted colonoscopy portfolio. Olympus commercially launched its OLYSENSE CAD/AI portfolio in the United States and Europe in 2025. Fujifilm also launched its ELUXEO 8000 Endoscopic Imaging System in 2025 and expanded its accompanying GI scope portfolio. The market effect extends beyond improved visualization. AI functionality increasingly forms part of platform competition as hospitals evaluate imaging systems, processors and software together. This supports the above-average growth outlook for AI-based imaging while giving established endoscopy companies opportunities to expand beyond hardware. Gastrointestinal Cancer Expands Multiple Device Categories GI cancers generate demand across diagnosis, biopsy, intervention and surveillance. Global GLOBOCAN 2024 estimates include more than 2.04 million new colorectal cancer cases, approximately 980,000 stomach cancer cases, 494,000 esophageal cancer cases and more than 531,000 pancreatic cancer cases. Colorectal cancer supports colonoscopy and polypectomy, gastric and esophageal cancers require upper endoscopy and biopsy, while pancreatic cancer supports EUS-guided tissue acquisition and biliary drainage. Cancer-related obstruction also creates demand for GI stents and feeding access. Consequently, cancer care connects several segments of the market rather than generating revenue for a single device category. Enteral Feeding Maintains Recurring Supportive-Care Demand Enteral feeding devices address patients who cannot maintain adequate oral nutrition because of neurological conditions, cancer or other long-term illnesses. Published evidence has placed U.S. PEG placement at approximately 160,000 to 200,000 procedures annually, while historical research estimated 437,882 patients receiving home enteral nutrition. Enteral feeding has a different commercial profile from diagnostic endoscopy. Placement creates an initial procedure-related device event, followed by longer-duration demand for feeding products and related supplies. North America Leads While Asia Pacific Gains Share North America accounts for an estimated 39.0% share or USD 6.42 billion in 2025 and is projected to reach USD 9.28 billion by 2032 at 5.4% CAGR. North America remains the largest regional market, supported by high endoscopy volumes, colorectal screening, advanced hospital infrastructure and early adoption of therapeutic and digital technologies. The United States performed approximately 23.5 million major GI endoscopies in 2022, including more than 15 million colonoscopies. The region is also an early market for AI-assisted endoscopy, advanced EUS platforms and redesigned duodenoscopes. Europe represents USD 4.44 billion in 2025, reaching USD 6.52 billion by 2032 at 5.6% CAGR. Europe benefits from organized colorectal screening and established endoscopy infrastructure. Asia Pacific accounts for approximately USD 4.12 billion in 2025 and is projected to reach USD 7.02 billion by 2032, registering the fastest regional CAGR of approximately 7.9%. Asia Pacific is positioned for faster growth as endoscopy access expands across large healthcare systems. China continues increasing digestive endoscopy capacity, Japan has a mature advanced-endoscopy environment, and companies such as Olympus and Fujifilm have extensive regional presence. These factors support an estimated 7.9% CAGR for Asia Pacific through 2032. Latin America represents approximately USD 0.82 billion in 2025, increasing to USD 1.25 billion by 2032 at 6.2% CAGR. Middle East & Africa account for approximately USD 0.66 billion in 2025 and are projected to reach USD 1.01 billion by 2032 at approximately 6.3% CAGR. Competition Broadens Across Complete GI Procedure Portfolios Major participants include Olympus, Boston Scientific, Fujifilm, Medtronic, Cook Medical, Ambu and PENTAX Medical. Boston Scientific reported USD 2.916 billion in Endoscopy net sales in 2025, compared with USD 2.687 billion in 2024, demonstrating the commercial scale of therapeutic endoscopy and related product categories. Olympus expanded its U.S. EUS portfolio and signed an exclusive global distribution agreement with EndoRobotics in 2026. Fujifilm continues developing its ELUXEO imaging portfolio, while Medtronic is expanding AI-assisted colonoscopy through GI Genius. Cook Medical introduced the Cold AcuSnare polypectomy snare and Caesar grasping forceps in the United States and Canada in March 2026. These launches illustrate how recurring accessories remain an important revenue component alongside large imaging systems. Analyst Perspective The gastrointestinal devices market is shifting toward broader procedure-based platforms that combine visualization, tissue acquisition, treatment and digital assistance. Endoscopic devices remain the largest product segment, while hemostasis products are positioned for faster growth as therapeutic procedures expand. Colorectal cancer represents the largest disease-related revenue segment because screening, polypectomy, biopsy and surveillance create repeated device use. Hospitals will retain the largest end-user position, but ASCs are projected to grow faster as suitable endoscopic procedures continue moving into outpatient care. Within technology, robotics-assisted surgery and AI-based imaging are positioned to outpace conventional endoscopy and laparoscopy, although endoscopy will remain the largest technology category through 2032. Geographically, North America remains the largest market, while Asia Pacific is expected to gain share as screening, endoscopy access and advanced procedural capacity expand. With the Gastrointestinal Devices Market projected to increase from USD 16.46 billion in 2025 to USD 25.08 billion by 2032 at a CAGR of 6.2%, growth will increasingly come from the combination of high-volume endoscopy, recurring therapeutic products, outpatient procedures, AI-assisted imaging and higher-value interventional care. Gastrointestinal Devices Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 16.46 Billion Revenue Forecast in 2032 USD 25.08 Billion Overall Growth Rate CAGR of 6.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Product Type, By Disease Type, By End User, By Technology, By Geography By Product Type Endoscopic Devices, Laparoscopic Devices, Gastrointestinal Stents, Biopsy Devices, Hemostasis Devices, Enteral Feeding Devices, Other GI Devices By Disease Type Colorectal Cancer, GERD, Inflammatory Bowel Disease (IBD), Gastrointestinal Bleeding, Peptic Ulcers, Other Gastrointestinal Diseases By End User Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Diagnostic Centers By Technology Endoscopy, Laparoscopy, Robotics-Assisted Surgery, Capsule Endoscopy, AI-Based Imaging By Region North America, Europe, Asia-Pacific, Latin America, Middle East and Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Rising gastrointestinal disease burden and colorectal cancer screening demand Growing adoption of AI-assisted imaging and advanced endoscopy platforms Expansion of minimally invasive procedures and outpatient endoscopy services Increasing focus on infection-control solutions and single-use GI devices Customization Option Available upon request Frequently Asked Question About This Report Q1. How big is the gastrointestinal devices market? A1. The global gastrointestinal devices market was valued at USD 16.46 billion in 2025 and is projected to reach USD 25.08 billion by 2032. Q2. What is the CAGR for the gastrointestinal devices market during the forecast period? A2. The gastrointestinal devices market is expected to grow at a CAGR of 6.2% from 2026 to 2032. Q3. Who are the major players in the gastrointestinal devices market? A3. Leading companies include Olympus, Boston Scientific, Fujifilm, Medtronic, Cook Medical, Ambu, and PENTAX Medical. Q4. Which segment dominates the gastrointestinal devices market? A4. Endoscopic Devices represent the leading product segment, supported by high colonoscopy volumes, therapeutic procedures, and advanced imaging adoption. Q5. What factors are driving growth in the gastrointestinal devices market? A5. Growth is driven by increasing GI disease burden, colorectal cancer screening, AI-assisted imaging adoption, minimally invasive procedures, and expansion of outpatient endoscopy services. Sources: Colorectal Screening and Gastrointestinal Disease Burden National Cancer Institute SEER Cancer Statistics U.S. Preventive Services Task Force Colorectal Cancer Screening Recommendation Centers for Disease Control and Prevention Inflammatory Bowel Disease Centers for Disease Control and Prevention Inflammatory Bowel Disease Therapeutic Endoscopy, GI Bleeding and Procedure Demand National Institute of Diabetes and Digestive and Kidney Diseases Gastrointestinal Bleeding American Society for Gastrointestinal Endoscopy Clinical Guidelines American Society for Gastrointestinal Endoscopy Clinical Guidelines National Institute of Diabetes and Digestive and Kidney Diseases Gallstones FDA Actions and Infection Control in Endoscopy U.S. Food and Drug Administration Duodenoscope Safety Communication U.S. Food and Drug Administration Duodenoscope Safety Communication U.S. Food and Drug Administration Medical Device Safety Communications U.S. Food and Drug Administration Medical Device Safety Communications AI-Based Imaging and Advanced Gastrointestinal Technologies U.S. Food and Drug Administration Artificial Intelligence and Machine Learning Enabled Medical Devices European Medicines Agency Artificial Intelligence in Healthcare European Medicines Agency Artificial Intelligence in Healthcare Table of Contents - Global Gastrointestinal Devices Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Disease Type, End User, Technology, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Disease Type, End User, Technology, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Disease Type, End User, and Technology Investment Opportunities in the Gastrointestinal Devices Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Endoscopic Devices, Hemostasis Devices, Ambulatory Surgical Centers, Robotics-Assisted Surgery, Capsule Endoscopy, and AI-Based Imaging Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Gastrointestinal Devices in Screening, Diagnostic Endoscopy, Therapeutic Endoscopy, Digital Imaging, and Minimally Invasive GI Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Infection-Control, and Device Reprocessing Requirements Role of Colorectal Screening, Therapeutic Endoscopy, Minimally Invasive Procedures, and Outpatient Endoscopy in Market Expansion AI-Based Imaging, Single-Use Endoscopy, Robotic Assistance, Capsule Endoscopy, and Digital GI Imaging Trends Global Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Endoscopic Devices Laparoscopic Devices Gastrointestinal Stents Biopsy Devices Hemostasis Devices Enteral Feeding Devices Other GI Devices Market Analysis by Disease Type: Colorectal Cancer GERD Inflammatory Bowel Disease (IBD) Gastrointestinal Bleeding Peptic Ulcers Other Gastrointestinal Diseases Market Analysis by End User: Hospitals Ambulatory Surgical Centers (ASCs) Specialty Clinics Diagnostic Centers Market Analysis by Technology: Endoscopy Laparoscopy Robotics-Assisted Surgery Capsule Endoscopy AI-Based Imaging Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Disease Type, End User, and Technology Country-Level Breakdown: United States Canada Mexico Europe Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Disease Type, End User, and Technology Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Disease Type, End User, and Technology Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Disease Type, End User, and Technology Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Gastrointestinal Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Disease Type, End User, and Technology Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Olympus Corporation Boston Scientific Corporation Fujifilm Holdings Corporation Medtronic plc Cook Medical Ambu A/S PENTAX Medical Competitive Landscape and Strategic Insights Benchmarking Based on Endoscopic Imaging Capability, Therapeutic Device Portfolio, Infection-Control Design, AI Integration, Procedure Support, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Endoscopic Devices and Digital Imaging Platform Positioning Hemostasis Devices, Gastrointestinal Stents, Biopsy Devices, and Enteral Feeding Device Competitiveness Robotics-Assisted Surgery, Capsule Endoscopy, and AI-Based Imaging Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Disease Type, End User, Technology, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance and Infection-Control Risk Analysis Technology Adoption Trends Across Endoscopy, Laparoscopy, Robotics-Assisted Surgery, Capsule Endoscopy, and AI-Based Imaging List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Disease Type, End User, and Technology (2025 vs. 2032) Global Gastrointestinal Devices Ecosystem and Value Chain Analysis